Phase 1/2 Study of VS-6766 + Sotorasib in G12C NSCLC Patients
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of VS-6766 in combination with sotorasib in
patients with G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to
prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.